Company intelligence / Profile preview

Venantius

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Venantius was a clinical-stage biotechnology company focused on developing small molecule therapeutics for inflammatory diseases, specifically inflammatory bowel disease (IBD). The company's lead program targeted the RORgammaT (RORγt) nuclear receptor, a key driver of Th17 cell differentiation and cytokine production. In 2021, Venantius merged with Oppilan Pharma and Zurex Pharma to form Ventyx Biosciences. This consolidation aimed to create a diversified pipeline of precision therapies for autoimmune and inflammatory disorders. The RORγt program, designated VTX608, was integrated into the Ventyx portfolio to address unmet needs in gastroenterology.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Venantius.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Venantius.

Explore the full profile